The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non–small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States for these patients.
from Cancer via ola Kala on Inoreader http://ift.tt/2iSaO6n
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου